However, there is variability in the individual responses of asthmatic patients to these classes of antiasthmatic drugs: higher bronchodilator use, increased bronchodilator responsiveness, higher eNO and eosinophil cationic protein levels, greater airway hyperresponsiveness and pulmonary function values are associated with a greater response to ICS treatment in children. The gene discussed is RNASE3; the disease is airway hyperresponsiveness.